Design of Nanoparticle-Based Carriers for Targeted Drug Delivery

Xiaojiao Yu(Dartmouth College), Zi Chen(Dartmouth College)

Journal of Nanomaterials

January 1, 2016

10.1155/2016/1087250

Cited by 261

Related Papers

Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy

|Blood|2016|191

Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib

|JAMA Oncology|2024|26

First-in-human study of lisaftoclax (APG-2575), a novel BCL-2 inhibitor (BCL-2i), in patients (pts) with relapsed/refractory (R/R) CLL and other hematologic malignancies (HMs).

|Journal of Clinical Oncology|2021|25

Lisaftoclax (APG-2575) Safety and Activity As Monotherapy or Combined with Acalabrutinib or Rituximab in Patients (pts) with Treatment-Naïve, Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (R/R CLL/SLL): Initial Data from a Phase 2 Global Study

|Blood|2022|16